Genome Editing in Human iPS Cells to Study and Cure Disease
Human iPS (induced pluripotent stem) cells have the potential to allow us to study diseases in virtually any type of human cell, and develop cell transplantation-based therapies. Our team is developing and improving genome editing technology in iPS cells. We are developing novel isogenic iPS cell-based disease models, and correcting mutations in iPS cells from patients, a critical step in transplantation-based therapies. Our current focus is on diseases affecting cardiomyocytes and hepatocytes. →More
News
2023. 1. 23. Contribute to an introductory book for genome editing.
2023. 1. 9. Interview of Anri Saito as a representative graduate student is out at the Institution's website (in Japanese).
2023. 1. 3. Results of transplantation of genome edited iPS cells into mice to deliver therapeutic molecules for Fabry disease in vivo are out at bioRxiv.
2022. 12. 2. Analysis of combinations, types, and frequencies of genome editing outcomes in individual human cells is out at iScience.
-Press release from TMiMS
2022. 11. 25. Lab trip to Mt. Takao
2022. 10. 19. Ittetsu Nakajima is selected for the Futaba Scholarship!!
2022. 7. 28. Yuga Yasuda is selected for the Yoshida Scholarship!!
2022. 5. 25. Yuga Yasuda wins the Dean's Award of Department of Science and Engineering, Chuo Univeristy.
2022. 5. 20. We take lab photos.
2022. 4. 1. Lanyu Huang joins the lab as a graduate student. Kayoko Shinozaki, Yuya Yasuda, and Kanata Imamura start thier BS theses in the lab.